Paul Kim
Net Worth
Last updated:
What is Paul Kim net worth?
The estimated net worth of Mr. Paul Kim is at least $33,700,423 as of 3 Sep 2024. He owns shares worth $4,518,505 as insider, has earned $27,152,638 from insider trading and has received compensation worth at least $2,029,280 in Fulgent Genetics, Inc..
What is the salary of Paul Kim?
Mr. Paul Kim salary is $253,660 per year as Chief Financial Officer in Fulgent Genetics, Inc..
How old is Paul Kim?
Mr. Paul Kim is 58 years old, born in 1967.
What stocks does Paul Kim currently own?
As insider, Mr. Paul Kim owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Fulgent Genetics, Inc. (FLGT) | Chief Financial Officer | 209,481 | $21.57 | $4,518,505 |
What does Fulgent Genetics, Inc. do?
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
Paul Kim insider trading
Fulgent Genetics, Inc.
Mr. Paul Kim has made 56 insider trades between 2017-2024, according to the Form 4 filled with the SEC. Most recently he sold 1,674 units of FLGT stock worth $36,763 on 3 Sep 2024.
The largest trade he's ever made was exercising 111,236 units of FLGT stock on 17 Aug 2020. As of 3 Sep 2024 he still owns at least 209,481 units of FLGT stock.
Fulgent Genetics key executives
Fulgent Genetics, Inc. executives and other stock owners filed with the SEC:
- Dr. Han Lin Gao FACMG, M.D., Ph.D., D.A.B.M.G., F.A.C.M.G. (58) Chief Scientific Officer & Laboratory Director
- Mr. Jian Xie (59) Chief Operating Officer
- Mr. Ming Hsieh (69) Chairman, Chief Executive Officer & Pres
- Mr. Paul Kim (58) Chief Financial Officer